AKT1 and hepatocellular carcinoma: IL7 and MAL2 promote Sorafenib resistance in hepatocellular carcinoma by enhancing JAK/STAT and PI3K/AKT signaling, while autophagy-inducing stapled peptides counteract this resistance by degrading resistance-related proteins and synergizing with Sorafenib.